Head-To-Head Survey: BioLargo (BLGO) & Its Rivals

BioLargo (NASDAQ:BLGO) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its rivals? We will compare BioLargo to similar companies based on the strength of its profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Valuation and Earnings

This table compares BioLargo and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.06
BioLargo Competitors	$6.63 billion	$204.21 million	65.95

BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLargo and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1282	1596	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 6.99%. Given BioLargo’s rivals higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its rivals.

Profitability

This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

BioLargo has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.78, meaning that their average stock price is 78% more volatile than the S&P 500.

Summary

BioLargo rivals beat BioLargo on 8 of the 10 factors compared.

BioLargo Company Profile

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.